Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod versus interferon beta-1b for cognitive dysfunction in relapsing-remitting multiple sclerosis
2010-023023-19Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2010
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple sclerosis (MS) comparing Gilenya arm with Interferon beta-1b arm (2 arms). Primary endpoints: Reduction of cognitive dysfunction progression after 18 months and Most sensitive cognitive test for treatment-group differences. Started Nov 2010; status: completed.
02
Drugs
fingolimodinterferon beta-1b
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2010-023023-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023023-19.